Plus   Neg

HeidelbergCement H1 Group Revenue Declines 10.4%

HeidelbergCement (HDELY.PK) reported a 10.4% decline in first-half revenues, hit by lower sales volume and changed business policy at HC Trading.

Group revenue decreased by 10.4% to €8,254 million compared to the previous year's €9,212 million. Excluding consolidation and exchange rate effects, the decline amounted to 10.2%.

The Group share of the net result for the period totalled loss €3,133 million compared to a profit of €212 million last year. The company noted that the Group share of net result for the period was impacted by non-recurring effect from impairments.

Loss per share for the period was €15.79 versus a profit of €1.07 reported in the same period of last year.

Excluding non-recurring effects from the impairment of goodwill and other assets, the Group share rose by 5% to €356 million from €340 million reported a year ago.

Dr Dominik von Achten, Chairman of the Managing Board of HeidelbergCement, said, "In the second quarter, revenue dropped in many countries, in some cases by double-digit percentages. Nevertheless, we achieved a good result, which was almost at the previous year's level. The successful implementation of our COPE action plan played a large part in this..."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite the coronavirus pandemic, retailers are prepared for an early start to the holiday shopping season by offering discounts earlier so that consumers can buy and receive the gifts they want in time, the National Retail Federation or NRF said. The NRF also said it is launching a nationwide consumer education campaign called "New Holiday Traditions". Facebook (FB) has revealed new messaging features for Instagram, which will make it easier for users to stay in touch with others across Facebook's family of apps. The main change is that people using the Messenger app can now reach Instagram users, and vice versa. The users can control where they receive... Regeneron Pharmaceuticals, Inc. announced positive first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 in COVID-19 patients. REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The company said it plans rapidly to discuss results with regulatory authorities.
Follow RTT